Bruker (BRKR) vs Cytek Biosciences (CTKB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Bruker (BRKR) has outperformed Cytek Biosciences (CTKB) over the past year, gaining 19.4% versus a gain of 4.1%. Over five years, BRKR leads with a -32.2% price change compared with -67.8% for CTKB. Bruker is the larger company by market cap ($8.62 billion vs $800.4 million), about 10.8 times the size.
On valuation, Bruker trades at a lower forward P/E (23.3x vs 87.4x for Cytek Biosciences). Bruker pays a dividend yielding 0.09%, while Cytek Biosciences does not currently pay one. Bruker converts more of its revenue into profit, with a net margin of -0.3% versus -33.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BRKR | CTKB |
|---|---|---|
| Share price | $56.46 | $6.12 |
| Market cap | $8.62B | $800.40M |
| 1-day change | -9.08% | -3.16% |
| YTD return | +19.85% | +21.19% |
| 1-year return | +19.44% | +4.08% |
| 5-year return | -32.16% | -67.82% |
| Forward P/E | 23.25 | 87.43 |
| EPS (TTM) | $-1.10 | $-0.63 |
| Dividend yield | 0.09% | 0.00% |
| Annual dividend | $0.05 | $0.00 |
| Revenue (latest FY) | $3.44B | $201.49M |
| Revenue growth (YoY) | +2.08% | +0.52% |
| Net income (latest FY) | $-8.60M | $-66.54M |
| Gross margin | 45.91% | 51.84% |
| Operating margin | 1.98% | -20.04% |
| Net margin | -0.25% | -33.02% |
| 52-week high | $68.98 | $6.39 |
| 52-week low | $32.37 | $3.31 |
| Distance from 52-week high | -18.15% | -4.15% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +20.44% | +6.21% |
| Average volume | 2.32M | 1.31M |
| Shares outstanding | 152.72M | 130.78M |
| Employees | 11,085 | 703 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bruker is about 10.8 times larger than Cytek Biosciences by market value ($8.62B vs $800.40M).
- BRKR has outperformed CTKB by 15.4 percentage points over the past year.
- Bruker is more profitable, keeping -0.3 cents of every revenue dollar as net income versus -33.0 cents for Cytek Biosciences.
About Bruker
BRKR stock →Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Industrials · Biotechnology: Laboratory Analytical Instruments · 11,085 employees
About Cytek Biosciences
CTKB stock →Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 703 employees
BRKR vs CTKB FAQ
Which is bigger, Bruker or Cytek Biosciences?
Bruker (BRKR) is larger, with a market capitalization of $8.62B compared with $800.40M for Cytek Biosciences (CTKB).
Which stock has performed better over the past year, BRKR or CTKB?
BRKR returned +19.44% over the past 12 months, compared with +4.08% for CTKB (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Bruker or Cytek Biosciences?
Bruker pays a dividend yielding 0.09%, while Cytek Biosciences does not currently pay a regular dividend.
Are Bruker and Cytek Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.